We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-14.04%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$324M
AUM Growth
-$68.1M
Cap. Flow
-$6.87M
Cap. Flow %
-2.12%
Top 10 Hldgs %
96.16%
Holding
15
New
–
Increased
2
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$1.54M
2
CDTX
Cidara Therapeutics
CDTX
+$221K

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$7.96M
2
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
+$660K
3
PVLA
Palvella Therapeutics
PVLA
+$18.2K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
1
Gossamer Bio
GOSS
$66.5M
$110M 33.96%
6,553,116
-400,300
-6% -$7.96M
REPL icon
2
Replimune Group
REPL
$814M
$70.7M 21.82%
5,103,455
– –
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$53.8M 16.6%
2,969,582
– –
TBIO
4
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$24.2M 7.46%
2,437,603
– –
IMUX icon
5
Immunic
IMUX
$182M
$13.7M 4.23%
137,149
– –
PRTK
6
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.2M 3.47%
2,600,410
– –
OBSV
7
DELISTED
ObsEva SA Ordinary Shares
OBSV
$8.32M 2.57%
999,364
– –
PRVL
8
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$8.21M 2.54%
668,908
– –
EPIX
9
DELISTED
ESSA Pharma
EPIX
$5.76M 1.78%
1,709,848
+625,000
+58% +$1.54M
TRVI icon
10
Trevi Therapeutics
TRVI
$2.49B
$5.68M 1.75%
1,263,408
– –
KYNB
11
Kyntra Bio
KYNB
$28.5M
$4.83M 1.49%
5,226
– –
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
$3.27M 1.01%
82,026
+6,586
+9% +$221K
PVLA
13
Palvella Therapeutics
PVLA
$1.98B
$2.56M 0.79%
9,384
-47
-0.5% -$18.2K
JNCE
14
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.76M 0.54%
529,965
– –
SNNA
15
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
– –
-758,610
Closed -$660K

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2019 Portfolio in Review

As of Q3 2019, Omega Fund Management held 15 positions worth $324M, down 17% from $392M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Omega Fund Management's Q3 2019 filing shows 2 increased, 2 reduced and 1 closed positions. The largest sale was Gossamer Bio, an estimated $7.96M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Omega Fund Management added most to ESSA Pharma in Q3 2019, an estimated $1.54M increase.
  • Omega Fund Management's biggest Q3 2019 reduction was Gossamer Bio, cutting an estimated $7.96M.
  • Omega Fund Management fully exited Sienna Biopharmaceuticals, Inc. in Q3 2019, selling an estimated $660K.
  • Omega Fund Management's ten largest holdings make up 96% of its $324M portfolio in Q3 2019.
  • Omega Fund Management opened 0 new positions and closed 1 in Q3 2019.
  • Omega Fund Management's portfolio value fell 17% quarter-over-quarter to $324M.

Based on Omega Fund Management's 13F filing for Q3 2019, filed 13 Nov 2019.